Inflammation, Joint Function Disorder, Pain
Conditions
Brief summary
N=64 RA patients either early or established disease diagnosed after ACR/EULAR criteria 2010 with unilateral persistent knee arthritis. They were randomly assigned into two groups; group 1 received genicular nerve block, group 2 intra-articular triamcinolone. Both groups were examined by SOLAR scoring system, Visual analogue scale (VAS) and Lysholm score at 0, 2 and 12 weeks. A semi-quantitative score was used to assess tenderness and swelling at the same intervals.
Interventions
DRUGBupivacaine hydrochloride 0.5% (Marcaine, Pfizer)
3 point genicular nerve block
DRUGtriamcinolone 40 milligrams (Kenacort, Bristol Myers Squip)
intra-articular injection of triamcinilone
Sponsors
Sohag University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Masking description
The participants does not know the nature of the injected material. Syringe was colored to cover it
Intervention model description
Group received nerve block and another group received steroid
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* RA patients * Age \> 18 * unilateral persistent knee arthritis
Exclusion criteria
* Participants with severe knee osteoarthritis * peripheral neuropathy * psoriatic arthritis * skin infection * or those who have allergy for Bupivacaine
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pain changes by VAS | at 0 time after 2 weeks and after 12 weeks | 0 means no pain and 10 means the most severe pain |
| SOLAR score for inflammation changes by ultrasound | at 0 time after 2 weeks and after 12 weeks | 0 means normal and 27 means the worst possible inflammation |
| Lysholm score for change in knee function | at 0 time after 2 weeks and after 12 weeks | 100 means the best performance and 0 means complete loss of function |
Countries
Egypt
Outcome results
None listed